Adverum Biotechnologies, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Laurent Fischer. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Laurent Fischer has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ADVM / Adverum Biotechnologies, Inc. CEO, PRESIDENT AND DIRECTOR, Director 87,488
US:CTIC / CTI BioPharma Corp Director 80,000
US:MIRM / Mirum Pharmaceuticals, Inc. Director 17,000
US:TBRA / Tobira Therapeutics, Inc. Chief Executive Officer, Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Laurent Fischer. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ADVM / Adverum Biotechnologies, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADVM / Adverum Biotechnologies, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2022-04-20 ADVM Fischer Laurent 25,000 1.1120 2,500 11.1200 27,800 84 1.7500 -23,425 -84.26
2021-12-09 ADVM Fischer Laurent 14,323 1.8500 1,432 18.5000 26,498
2021-12-08 ADVM Fischer Laurent 10,677 1.7900 1,068 17.9000 19,112
2021-03-24 ADVM Fischer Laurent 10,000 9.8780 1,000 98.7800 98,780
2021-01-15 ADVM Fischer Laurent 8,600 11.5338 860 115.3380 99,191
2020-08-17 ADVM Fischer Laurent 7,692 13.0000 769 130.0000 99,996

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ADVM / Adverum Biotechnologies, Inc. Insider Trades
Insider Sales ADVM / Adverum Biotechnologies, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADVM / Adverum Biotechnologies, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-05-15 ADVM Fischer Laurent 9,126 2.0000 9,126 2.0000 18,252 0 2.0500 456 2.50
2023-03-15 ADVM Fischer Laurent 41,239 0.7816 4,124 7.8160 32,232
2022-09-19 ADVM Fischer Laurent 41,082 1.0696 4,108 10.6960 43,941

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ADVM / Adverum Biotechnologies, Inc. Insider Trades
Insider Purchases MIRM / Mirum Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADVM / Adverum Biotechnologies, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2019-09-17 MIRM Fischer Laurent 1,648 9.3660 1,648 9.3660 15,435 328 26.59 28,385 183.90
2019-09-16 MIRM Fischer Laurent 452 9.4700 452 9.4700 4,280
2019-09-10 MIRM Fischer Laurent 960 10.2932 960 10.2932 9,881
2019-09-09 MIRM Fischer Laurent 1,670 10.5400 1,670 10.5400 17,602
2019-09-09 MIRM Fischer Laurent 300 11.3000 300 11.3000 3,390
2019-09-06 MIRM Fischer Laurent 1,720 10.7147 1,720 10.7147 18,429

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MIRM / Mirum Pharmaceuticals, Inc. Insider Trades
Insider Sales MIRM / Mirum Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADVM / Adverum Biotechnologies, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MIRM / Mirum Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Laurent Fischer as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-05-16 2025-05-15 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
S - Sale -9,126 87,488 -9.45 2.00 -18,252 174,976
2025-02-27 2025-02-25 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
A - Award 25,000 96,614 34.91
2023-03-17 2023-03-15 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
S - Sale -41,239 692,141 -5.62 0.78 -32,232 540,977
2022-09-21 2022-09-19 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
S - Sale -41,082 727,380 -5.35 1.07 -43,941 778,006
2022-04-22 2022-04-20 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
P - Purchase 25,000 762,462 3.39 1.11 27,800 847,858
2022-03-17 2022-03-08 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
A - Award 630,000 630,000
2022-03-11 2022-03-09 4 CTIC CTI BIOPHARMA CORP
Stock Option (right to buy)
A - Award 80,000 80,000
2021-12-10 2021-12-09 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
P - Purchase 14,323 737,462 1.98 1.85 26,498 1,364,305
2021-12-10 2021-12-08 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
P - Purchase 10,677 723,139 1.50 1.79 19,112 1,294,419
2021-08-10 2021-08-06 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
A - Award 455,000 455,000
2021-08-10 2021-08-06 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
A - Award 680,000 706,292 2,586.34
2021-06-08 2021-06-04 4 MIRM Mirum Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 17,000 17,000
2021-03-24 2021-03-24 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
P - Purchase 10,000 26,292 61.38 9.88 98,780 259,712
2021-03-12 2021-03-10 4 CTIC CTI BIOPHARMA CORP
Stock Option (right to buy)
A - Award 80,000 80,000
2021-02-18 2021-02-16 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
A - Award 680,000 680,000
2021-01-19 2021-01-15 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
P - Purchase 8,600 16,292 111.80 11.53 99,191 187,909
2020-08-19 2020-08-17 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
P - Purchase 7,692 7,692 13.00 99,996 99,996
2020-06-17 2020-06-15 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
A - Award 1,200,000 1,200,000
2020-06-17 3 ADVM Adverum Biotechnologies, Inc.
No securities owned.
0
2020-06-15 2020-06-11 4 MIRM Mirum Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 17,000 17,000
2020-03-13 2020-03-11 4 CTIC CTI BIOPHARMA CORP
Non-qualified Stock Option
A - Award 126,000 126,000
2019-09-18 2019-09-17 4 MIRM Mirum Pharmaceuticals, Inc.
Common Stock
P - Purchase 1,648 6,750 32.30 9.37 15,435 63,220
2019-09-18 2019-09-16 4 MIRM Mirum Pharmaceuticals, Inc.
Common Stock
P - Purchase 452 5,102 9.72 9.47 4,280 48,316
2019-09-10 2019-09-10 4 MIRM Mirum Pharmaceuticals, Inc.
Common Stock
P - Purchase 960 4,650 26.02 10.29 9,881 47,863
2019-09-10 2019-09-09 4 MIRM Mirum Pharmaceuticals, Inc.
Common Stock
P - Purchase 300 3,690 8.85 11.30 3,390 41,697
2019-09-10 2019-09-09 4 MIRM Mirum Pharmaceuticals, Inc.
Common Stock
P - Purchase 1,670 3,390 97.09 10.54 17,602 35,731
2019-09-10 2019-09-06 4 MIRM Mirum Pharmaceuticals, Inc.
Common Stock
P - Purchase 1,720 1,720 10.71 18,429 18,429
2019-05-20 2019-05-16 4 ctic CTI BIOPHARMA CORP
Non-Qualified Stock Option (right to buy)
A - Award 120,000 120,000
2018-05-17 2018-05-17 4 ctic CTI BIOPHARMA CORP
Non-Qualified Stock Option (right to buy)
A - Award 60,000 60,000
2017-07-25 2017-07-21 4 CTIC CTI BIOPHARMA CORP
Stock Option (Right to Buy)
A - Award 50,000 50,000
2017-07-25 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share
0
2016-11-03 2016-11-01 4 TBRA Tobira Therapeutics, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -258,000 0 -100.00
2016-11-03 2016-11-01 4 TBRA Tobira Therapeutics, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -105,000 0 -100.00
2016-11-03 2016-11-01 4 TBRA Tobira Therapeutics, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -503,882 0 -100.00
2016-11-03 2016-11-01 4 TBRA Tobira Therapeutics, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -83,324 0 -100.00
2016-11-03 2016-11-01 4 TBRA Tobira Therapeutics, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -16,416 0 -100.00
2016-11-03 2016-11-01 4 TBRA Tobira Therapeutics, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -53,616 0 -100.00
2016-11-03 2016-11-01 4 TBRA Tobira Therapeutics, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -4,332 0 -100.00
2016-11-03 2016-11-01 4 TBRA Tobira Therapeutics, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -4,332 0 -100.00
2016-01-14 2016-01-12 4 TBRA Tobira Therapeutics, Inc.
Stock Options (right to buy)
A - Award 258,000 258,000
2015-05-18 2015-05-15 4 TBRA Tobira Therapeutics, Inc.
Stock Options (right to buy)
A - Award 105,000 105,000
2015-05-06 2015-05-04 4 TBRA Tibira Therapeutics, Inc.
Stock Options (right to buy)
A - Award 503,882 672,671 298.53
2015-05-06 2015-05-04 4 TBRA Tibira Therapeutics, Inc.
Stock Options (right to buy)
A - Award 83,324 168,789 97.49
2015-05-06 2015-05-04 4 TBRA Tibira Therapeutics, Inc.
Stock Options (right to buy)
A - Award 6,769 85,465 8.60
2015-05-06 2015-05-04 4 TBRA Tibira Therapeutics, Inc.
Stock Options (right to buy)
A - Award 16,416 78,696 26.36
2015-05-06 2015-05-04 4 TBRA Tibira Therapeutics, Inc.
Stock Options (right to buy)
A - Award 53,616 62,280 618.84
2015-05-06 2015-05-04 4 TBRA Tibira Therapeutics, Inc.
Stock Options (right to buy)
A - Award 4,332 8,664 100.00
2015-05-06 2015-05-04 4 TBRA Tibira Therapeutics, Inc.
Stock Options (right to buy)
A - Award 4,332 8,664 100.00
2015-05-06 3 TBRA Tibira Therapeutics, Inc.
Common Stock
0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)